Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma

Medicus Pharma Ltd ( (MDCX) ) has shared an announcement.

Medicus Pharma has released an interpretation of Phase 2 data for its SkinJect microneedle delivery system in basal cell carcinoma, highlighting that the 200‑µg cohort achieved 73% clinical clearance and 40% histological clearance by Day 57, the strongest response in the trial. The study showed a clear efficacy separation between the drug‑loaded microneedle arm and the active placebo device arm, supporting the view that SkinJect delivers additional therapeutic benefit beyond the biologic effects of microneedle‑induced tumor disruption and reinforcing its potential as a non‑surgical treatment that could reduce reliance on Mohs surgery and underpin upcoming regulatory discussions and strategic partnership efforts.

The company emphasized that microneedle insertion itself can trigger immune and wound‑healing responses, explaining meaningful activity in the placebo arm but noting that basal cell carcinoma’s immunogenic nature makes the added drug effect particularly important. With basal cell carcinoma being the world’s most common cancer, Medicus argues that the Phase 2 dataset provides decision‑grade evidence for advancing SkinJect, potentially offering dermatologists a minimally invasive option that may allow many patients whose lesions clear visually to delay or avoid immediate surgery while being monitored in routine practice.

The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.

Spark’s Take on MDCX Stock

According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.

To see Spark’s full report on MDCX stock, click here.

More about Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech and life sciences company developing novel, potentially disruptive therapeutic assets, with a current focus on device‑drug combination therapies. Its SkinJect microneedle platform targets basal cell carcinoma, aiming to offer a minimally invasive, non‑surgical alternative in the large and growing dermatologic oncology market.

Average Trading Volume: 1,099,260

Technical Sentiment Signal: Sell

Current Market Cap: $9.9M

See more data about MDCX stock on TipRanks’ Stock Analysis page.